Johnson & Johnson to Pay $2.2 Billion to Settle Allegations of Marketing Irregularities

by Kathy Jones on  November 8, 2013 at 9:41 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

The US Justice Department has revealed that American drugs company Johnson & Johnson has agreed to pay over $2.2 billion as part of the settlement of allegations over its marketing techniques.
 Johnson & Johnson to Pay $2.2 Billion to Settle Allegations of Marketing Irregularities
Johnson & Johnson to Pay $2.2 Billion to Settle Allegations of Marketing Irregularities

The company had been accused of paying incentives to doctors and pharmacies in order to promote three of its medicines, including anti-psychotic drugs Risperdal and Invega and heart drug Natrecor.

The company has also been accused of promoting drugs for uses not officially allowed.

"They lined their pockets at the expense of the American taxpayers, patients and the private insurance industry. They drove up costs for everyone in the healthcare system and negatively impacted the long term solvency of the central healthcare programmes like Medicare", US Attorney General Eric Holder said.



Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive